AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20864423
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral 5% glucose infusion (25 ml h(‐1) via jejunostomy tube initiated 6h after surgery)
Trial: 20864423
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (peripheral parenteral nutrition for seven post-operation days)
Trial: 20864423
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral 5% glucose infusion
Trial: 14594748
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for the first 28 days and 10 mg/day thereafter)
Trial: 9707356
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg PETN
Trial: 9707356
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg PETN
Trial: 9707356
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg GTN
Trial: 2650539
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lovastatin twice daily for 6 weeks
Trial: 2650539
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lovastatin twice daily for 6 weeks
Trial: 2650539
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg lovastatin twice daily for 6 weeks
Trial: 2650539
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg lovastatin twice daily
Trial: 2650539
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lovastatin twice daily
Trial: 2650539
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lovastatin twice daily
Trial: 2650539
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the first 6 weeks followed by stepped doses of lovastatin
Trial: 31583989
Drug: Post-treatment remitted
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment remitted DM+
Trial: 31583989
Drug: Post-treatment remitted
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment remitted DM-
Trial: 31102328
Drug: High oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oxygen therapy (≥96% SpO2)
Trial: 31102328
Drug: Low oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low oxygen therapy (90–92% SpO2)
Trial: 26920551
Drug: Perceived needs
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived needs for substance treatment services
Trial: 21980881
Drug: Deepwave treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deepwave treatment
Trial: 9042992
Drug: Ondansetron (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.3 mg/kg)
Trial: 9042992
Drug: Metoclopramide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.3 mg/kg)
Trial: 16353616
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg/d)
Trial: 16353616
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Fluoxetine and Placebo)
Trial: 30087555
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg fimasartan
Trial: 30087555
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of fimasartan and atorvastatin
Trial: 25763853
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronic acid (HA) post-operatively
Trial: 23270248
Drug: Kang'ai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kang'ai injection with chemotherapy
Trial: 12759389
Drug: Beta-carotene (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (25 mg)
Trial: 8481254
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) with or without dipyridamole (D)
Trial: 8481254
Drug: Anticoagulants (AC)
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (AC)
Trial: 8481254
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) + Anticoagulants (AC)
Trial: 8481254
Drug: Low (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low (100 mg) to medium (325 mg) daily aspirin dosage
Trial: 8481254
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative treatment (< or = 6 h)
Trial: 8481254
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of aspirin
Trial: 29672392
Drug: Hyperoxygenated fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperoxygenated fatty acids (HOFAs) treatment
Trial: 26969090
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg per day orally for 54 weeks
Trial: 26969090
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice per day orally for 54 weeks
Trial: 18517133
Drug: Trimecaine 50
RxNorm normalized name: tricaine
DrugBank: Tricaine (DB11552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimecaine 50 mg with 4 mg morphine administered epidurally in 8 hour intervals
Trial: 18517133
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% and fentanyl 2 microg/ml administered at an infusion rate of 8 ml/h
Trial: 18517133
Drug: Trimecaine with
RxNorm normalized name: tricaine
DrugBank: Tricaine (DB11552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimecaine with morphine
Trial: 10522523
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH (0.005 mg/kg per day)
Trial: 10522523
Drug: High-dose ACTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ACTH (0.025 mg/kg per day)
Trial: 8748907
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 70 mg/kg (group A)
Trial: 8748907
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 100 mg/kg (group B)
Trial: 7025554
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 12‐50 microgram/min of salbutamol (Ventoline) and 4 mg orally at 4‐hour intervals
Trial: 7025554
Drug: Fenoterol, 3‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol, 3‐4 microgram/min and subsequently 5 mg orally at 4‐hour intervals
Trial: 28230742
Drug: GLU +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU + FRU (1.2 g∙min‐1 glucose + 0.6 g∙min‐1 fructose)
Trial: 28230742
Drug: GLU +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU + SUC (0.6 g∙min‐1 glucose + 1.2 g∙min‐1 sucrose)
Trial: 28230742
Drug: GLU (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU (1.8 g∙min‐1 glucose)
Trial: 25912752
Drug: Trabectedin 3-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 3-hour infusion (T3h)
Trial: 25912752
Drug: Trabectedin 24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 24-hour infusion (T24h)
Trial: 15513495
Drug: Continuous intraarticular
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraarticular morphine 20 mg/mL, 0.5 mL plus ropivacaine 2 mg/mL, 100 mL; bolus 20 mL and 2 mL/hour from 24 to 72 hours postoperatively (group 2)
Trial: 15513495
Drug: Double the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double the dose of continuous intraarticular morphine and ropivacaine (4 mL/hour from 24 to 72 hours postoperatively) (group 3)
Trial: 15513495
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative analgesics (group 1)
Trial: 15513495
Drug: Continuous intraarticular
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraarticular morphine and ropivacaine (group 2 and group 3)
Trial: 2883777
Drug: Vasodilators (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilators (including nitrates and alpha-receptor blocking agents)
Trial: 28110949
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide (500 mg) administration 1 hour preoperatively
Trial: 28110949
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide (500 mg) administration 3 hours postoperatively
Trial: 28110949
Drug: No acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No acetazolamide administration
Trial: 21418045
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric bupivacaine 7.5 mg
Trial: 21418045
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric bupivacaine 7.5 mg followed by epidural volume extension with saline 5 ml
Trial: 21418045
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric bupivacaine 10 mg without epidural volume extension
Trial: 12136518
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation therapy (BCT) with lumpectomy and radiation
Trial: 12136518
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by BCT
Trial: 12136518
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of chest wall and regional lymphatic irradiation to adjuvant systemic therapy
Trial: 7977523
Drug: Nafarelin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin therapy (200 micrograms intranasally twice a day for 3 months)
Trial: 7977523
Drug: Nafarelin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin therapy (200 micrograms intranasally twice a day for 6 months)
Trial: 7977523
Drug: Nafarelin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin therapy (both 3 and 6 months)
Trial: 7977523
Drug: Nafarelin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin therapy
Trial: 29141361
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg twice daily for day 0 to day 3 after PCI
Trial: 18306904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional therapy only)
Trial: 21372624
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Treatment (CBT)
Trial: 23607895
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Treatment supported by Information and Communication Technologies (CBT + ICT)
Trial: 21310077
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (lisinopril, losartan, atorvastatin)
Trial: 15378097
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (referrals to physical therapy and/or rehabilitation)
Trial: 11331630
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix, 0.25 mg daily during late follicular phase)
Trial: 21945081
Drug: Low-dose bupivacaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bupivacaine
Trial: 30866853
Drug: PCV13 vaccine
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 vaccine serotypes
Trial: 28395984
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (MT) including neurodynamic techniques, functional massage, and carpal bone mobilization
Trial: 28395984
Drug: Electrophysical Modalities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysical Modalities (EM) including laser and ultrasound therapy
Trial: 17148774
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cyclophosphamide administered concurrently
Trial: 17148774
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cyclophosphamide administered sequentially
Trial: 12962749
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with polyclonal or monoclonal antilymphocytic antibodies associated with cyclosporine and prednisone (n=201)
Trial: 10078748
Drug: withdrawn from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: withdrawn from therapy (n = 4)
Trial: 8742561
Drug: Intensive diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive diabetes treatment
Trial: 8742561
Drug: Conventional diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diabetes treatment
Trial: 3316309
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg + Amiloride 5 mg
Trial: 1682228
Drug: Diuretic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic group
Trial: 25744453
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with organoleptic masking (L-menthol, aspartame, thaumatin, cinnamon) and physical masking
Trial: 25744453
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with physical masking
Trial: 25744453
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) without organoleptic masking
Trial: 10841922
Drug: Glyceroltrinitrate (GTN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceroltrinitrate (GTN; 0.4 mg/h)
Trial: 10841922
Drug: Glyceroltrinitrate (GTN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceroltrinitrate (GTN; 0.4 mg/h) + Vitamin C (Vit-C; 55 μg/kg/min)
Trial: 10841922
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (Vit-C; 55 μg/kg/min) alone
Trial: 8905031
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of L-asparaginase (L-ASE) 10,000 IU/sqm every three days during the induction phase (8 doses, first exposure)
Trial: 8905031
Drug: Conventional or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional or high doses of L-asparaginase (L-ASE) during the second or third exposures (high-dose L-ASE 25,000 IU/sqm weekly for a total of 20 doses)
Trial: 22805300
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml isotonic saline (placebo)
Trial: 12051112
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (Menorest, 50 micrograms)
Trial: 9797622
Drug: Both morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both morphine and diamorphine
Trial: 7618661
Drug: 51W89 besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51W89 besylate 0.1 mg.kg‐1
Trial: 7618661
Drug: 51W89 besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51W89 besylate 0.15 mg.kg‐1
Trial: 7618661
Drug: 51W89 besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51W89 besylate 0.2 mg.kg‐1
Trial: 7916551
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1
Trial: 368703
Drug: Chlorprothixene 50
RxNorm normalized name: chlorprothixene 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene 50 mg b.d. (twice daily) to outpatients
Trial: 368703
Drug: Chlorprothixene 50
RxNorm normalized name: chlorprothixene 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene 50 mg every 6 hours to inpatients for 5 days
Trial: 28891826
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 0.375% ropivacaine
Trial: 21806387
Drug: CYP2C19 genotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotypes (gene-dose effect)
Trial: 17098626
Drug: Epaxal (aluminium-free,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epaxal (aluminium-free, virosome-adjuvanted vaccine)
Trial: 17098626
Drug: Havrix (aluminium-adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix (aluminium-adsorbed HAV vaccine)
Trial: 15517641
Drug: Corticosteroid (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (80 mg triamcinolone acetonide)
Trial: 9332238
Drug: alpha 1-antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha 1-antitrypsin augmentation therapy
Trial: 29331635
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg sotatercept
Trial: 29331635
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg sotatercept
Trial: 29331635
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg sotatercept
Trial: 29331635
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg sotatercept
Trial: 29331635
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg sotatercept
Trial: 29331635
Drug: Sotatercept (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (all doses)
Trial: 27636206
Drug: HMW carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Trial: 27636206
Drug: LMW carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW carbohydrate solution (1.2 g•kg•bw‐1 of 10%)
Trial: 27636206
Drug: HMW vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMW vs LMW carbohydrate solutions
Trial: 27636206
Drug: Both HMW
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HMW and LMW carbohydrate solutions
Trial: 22335889
Drug: Short-term psychotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychotherapy (solution-focused or psychodynamic therapy, combined)
Trial: 25454120
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy
Trial: 16314604
Drug: Paroxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (up to 50 mg/day for 31 days)
Trial: 6871773
Drug: Zomepirac 100
RxNorm normalized name: zomepirac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac 100 mg administered 30 minutes preoperatively
Trial: 6871773
Drug: Zomepirac 100
RxNorm normalized name: zomepirac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac 100 mg administered one hour preoperatively
Trial: 6871773
Drug: Zomepirac 200
RxNorm normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac 200 mg administered one hour preoperatively